Introduction
============

The safety of a drug product is not only dependent on the toxicological properties of the active drug substance (or API), but also on the impurities formed during the various chemical transformations. Therefore, identification, quantification, and control of impurities in the drug substance and drug product are important parts of drug development for obtaining marketing approval. It is more challenging for an organic chemist to identify the impurities which are formed in very small quantities in a drug substance. Since most of the time it is very difficult to identify and control impurities within acceptable levels in the process, extra purification steps may then be necessary thereby making the process less competitive. More often than not, the syntheses of impurities are not described in the literature which makes it even more difficult for the organic chemist who must then design a synthesis, which is time consuming. The development of a drug substance is incomplete without the identification of an impurity profile involved in the process. Furthermore, it is not mandatory to design synthetic routes for the impurities. Thus, in our study we explored the formation, identification, synthesis and characterization of impurities found in the preparation of sertindole. This study will be of immense help for organic chemists to understand the potential impurities in sertindole synthesis and thereby obtain the pure compound.

Sertindole (**1**) ([Fig. 1](#F1){ref-type="fig"})**,** displays broad pharmacological profile and mainly affects dopamine D~2~, serotonin 5-HT~2~ and α~1~-adrenergic receptors \[[@R1]--[@R5]\]. It is a potent centrally acting 5-HT~2~ receptor antagonist in vivo and finds application in the treatment of anxiety, hypertension, drug abuse and cognitive disorders. It has been reported to show antipsychotic effect in clinical studies. In contrast to other antipsychotics, sertindole has no associated sedative effects; sedation may add to the cognitive problems inherent in schizophrenia.

![Sertindole (**1**), process related impurities and metabolites.](Beilstein_J_Org_Chem-07-29-02){#F1}

Sertindole is designated chemically as 1-\[2-\[4-\[5-chloro-1-(4-fluorophenyl)-1*H*-indol-3-yl\]-1-piperidinyl\]ethyl\]-2-imidazolidinone. Its literature synthesis ([Scheme 1](#C1){ref-type="fig"}) \[[@R1]--[@R5]\] involves the copper catalyzed *N*-arylation of 5-chloroindole (**11**) with 4-fluorobromobenzene (**12**). The product, 5-chloro-1-(4-fluorophenyl)indole (**13**), on treatment with 4-piperidinone hydrochloride monohydrate (**14**) under acidic conditions affords 5-chloro-1-(4-fluorophenyl)-3-(1,2,3,6-tetrahydropyridin-4-yl)-1*H*-indole hydrochloride (**15**)**.** Reduction of **15** in the presence of platinum oxide yields 5-chloro-1-(4-fluorophenyl)-3-(4-piperdinyl)-1*H*-indole (**9**) which on condensation with 1-(2-chloroethyl)imidazolidinone (**16**) in the presence of a base gives sertindole (**1**).

![Reagents and conditions: i) K~2~CO~3~, CuBr, ethylenediamine, DMF 130--135 °C; ii) CH~3~COOH, CF~3~COOH, 100--110 °C; iii) PtO~2~/H~2~, methanol, 30--35 °C; iv) K~2~CO~3~, KI, methylisobutyl ketone (MIBK),110--115 °C.](Beilstein_J_Org_Chem-07-29-03){#C1}

During the laboratory optimization of sertindole (**1**), many process related impurities were identified. The guidelines recommended by ICH state that the acceptable levels for a known and unknown compound (impurity) in the drug should be less than 0.15 and 0.10%, respectively \[[@R6]\]. In order to meet the stringent regulatory requirements, the impurities present in the drug substance must be identified and characterized. Literature reports \[[@R5],[@R7]--[@R9]\] include impurities formed due to either over reduction (e.g., **2**, **3** and **6**) \[[@R5],[@R7]\], incomplete reduction (e.g., **4** and **5**) \[[@R5],[@R8]\] or due to incomplete alkylation (e.g., **9** and **10**) \[[@R5],[@R7]\]. However, no synthetic details have been reported. In this context, the present study describes identification, synthesis and characterization of impurities formed during sertindole synthesis.

Results and Discussion
======================

During the catalytic hydrogenation of indole **15,** formation of 0.5--1.0% of the des-chloro indole **17** is observed; the level is reduced to less than 0.1% during its isolation and purification. It is necessary to remove the impurity at this stage because after condensation with imidazolidinone **16**, it is difficult to remove the des-chloro sertindole **2**, from sertindole, without significant loss in yield. The impurity **2** was prepared by palladium catalyzed hydrogenation of indole **9** and the des-chloro indole **17** formed was condensed with imidazolidinone **16**, under Finkelstein conditions ([Scheme 2](#C2){ref-type="fig"}).

![Reagents, conditions (and yields): i) (a) pH adjusted to 6; (b) Pd/C, HCOONH~4~, AcOH, MeOH, reflux (77.6%); ii) **16**, K~2~CO~3~, KI, MIBK, reflux (44.5%).](Beilstein_J_Org_Chem-07-29-04){#C2}

The platinum catalyzed reduction of indole **15** is a critical reaction, whilst a prolonged reaction time leads to dehalogenated product **2**, termination without complete reduction leads to indole **9** contaminated with **15**. This contaminated material upon condensation with imidazolidinone **16** results in sertindole (**1**) contaminated with **5**. The degree of contamination was 0.02--0.10% \[[@R10]\]. It is difficult to remove the impurity **5** from sertindole (**1**). Indole **5** was prepared by condensation of **15** with 1-(2-chloroethyl)imidazolidinone (**16**) in the presence of base ([Scheme 3](#C3){ref-type="fig"}).

![Reagents, conditions (and yields): i) **16**, K~2~CO~3~, KI, MIBK, reflux (73.9%).](Beilstein_J_Org_Chem-07-29-05){#C3}

During the *N*-arylation of 5-chloroindole (**11**) with 1-bromo-4-fluorobenzene (**12**), formation of traces of 5-chloro-1-(4-bromophenyl) indole (**18**) along with the desired indole **13** was observed. A detail study of this coupling reaction revealed significant formation of this undesired indole in the absence of a transition metal, especially when cesium carbonate was used for the coupling reaction. Sertindole (**1**) synthesized from this contaminated material was found to contain impurity **21** at levels of 0.05--0.25% \[[@R10]\]. In order to quantify and limit the impurities in the final drug substance, indole **18** was converted to the corresponding *N*-(4-bromophenyl)-impurity **21** ([Scheme 4](#C4){ref-type="fig"}). The catalytic hydrogenation of indole **19** proved to be a difficult reaction as significant formation of the dehalogenated products was observed, repeated recrystallization from MeOH afforded pure indole **20**.

![Reagents, conditions (and yields): i) Cs~2~CO~3~, DMF, 130--135 °C; ii) **14**, CH~3~COOH, CF~3~COOH, 100--105 °C (43.4% from **11**); iii) (a) pH adjusted to 6--7; (b) H~2~, PtO~2~, MeOH, AcOH, 30--35 °C; (c) crystallization (24.7%); iv) **16**, K~2~CO~3~, KI, MIBK, reflux (65% yield).](Beilstein_J_Org_Chem-07-29-06){#C4}

Since dehalogenation was observed during the platinum oxide reduction of the tetrahydropyridinyl moiety in indole **19**, this reaction was utilized to synthesize the des-fluoro sertindole **3**. Thus prolonged hydrogenation of **19** afforded des-fluoro indole **22**, which on condensation with imidazolidinone **16** afforded the desired compound **3** ([Scheme 5](#C5){ref-type="fig"}). The contamination by **3** in sertindole (**1**) was 0.20--0.50% \[[@R10]\].

![Reagents, conditions (and yields): i) (a) pH adjusted to 6--7; (b) H~2~, PtO~2~, MeOH, AcOH, 30--35 °C (73% yield); ii) **16**, K~2~CO~3~, KI, MIBK, reflux (52%).](Beilstein_J_Org_Chem-07-29-07){#C5}

In some of commercial samples, 5-chloroindole was found to be contaminated with traces of 5-bromoindole (**23**), although the amount of contamination of the bromo analogue **27** in sertindole (**1**) was never more than 0.02%. The bromo analogue of sertindole (**27**) was synthesized from 5-bromoindole (**23**) following the reaction sequence used to synthesize **1** ([Scheme 6](#C6){ref-type="fig"}).

![Reagents, conditions (and yields): i) **12**, K~2~CO~3~, Cu(II)Br, ethylenediamine, DMF, 130--135 °C, (51%); ii) **14**, CH~3~COOH, CF~3~COOH, 100--105 °C (57%); iii) (a) pH adjusted to 6--7; (b) PtO~2~/H~2~, MeOH, 30--35 °C; (c) column chromatography (33.3%); iv) **16**, K~2~CO~3~, KI, MIBK, reflux (64.3%).](Beilstein_J_Org_Chem-07-29-08){#C6}

During the *N*-alkylation reaction there is always the probability of dialkylation, hence the dialkylated piperidine **28** was synthesized by prolonged condensation of imidazolidinone **16** with sertindole (**1**)**,** followed by purification by column chromatography ([Scheme 7](#C7){ref-type="fig"}). The contamination by **28** in sertindole (**1**) was 0.25--0.45% \[[@R10]\].

![Reagents, conditions (and yield): i) (a) **16**, Et~3~N, NaI, CH~3~CN, reflux; (b) column chromatography (19.1%).](Beilstein_J_Org_Chem-07-29-09){#C7}

Sertindole *N*-oxide **29,** a possible contaminant that can be formed by air oxidation, was prepared by oxidation of sertindole (**1**) with *m*-chloroperbenzoic acid ([Scheme 8](#C8){ref-type="fig"}). The contamination by **29** in sertindole (**1**) was \<0.05% \[[@R10]\].

![Reagents, conditions (and yield): i) (a) mCPBA, MeOH, 40--45 °C; (b) column chromatography (52.2%).](Beilstein_J_Org_Chem-07-29-10){#C8}

Conclusion
==========

For the better understanding of the synthetic pathway of an active pharmaceutical ingredient (API) it is necessary to identify all the impurities formed/anticipated. In this regard we have synthesized and characterized different potential process-related impurities of sertindole.

Supporting Information
======================

Experimental procedure ([Supporting Information File 1](#SD1){ref-type="supplementary-material"}); HPLC chromatograms, ^1^H and ^13^C NMR spectra of compounds **2**, **3**, **5**, **9**, **21**, **27**, **28** and **29** ([Supporting Information File 2](#SD2){ref-type="supplementary-material"}). HPLC chromatogram containing sertindole (**1**) spiked with process related impurities and LC-MS fragmentation data \[[@R10]\] is included in [Supporting Information File 2](#SD2){ref-type="supplementary-material"}.

###### 

Full experimental details and characterization data for all new compounds.

###### 

^1^H and ^13^C NMR spectral data and HPLC chromatograms for all new compounds.
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